Clinical Trials · NCT02268175
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 75
- Start date
- Oct 2014
- Locations
- 4 sites, United States
- Primary endpoint
- Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD)